Get the Stockscreener App
16.73
2.14%
0.35
Moonlake Immunotherapeutics stock is traded at $16.73, with a volume of 852.46K.
It is up +2.14% in the last 24 hours and up +1.27% over the past month.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
See More
Previous Close:
$16.38
Open:
$16.43
24h Volume:
852.46K
Relative Volume:
0.76
Market Cap:
$1.22B
Revenue:
-
Net Income/Loss:
$-230.32M
P/E Ratio:
-4.7449
EPS:
-3.5259
Net Cash Flow:
$-196.04M
1W Performance:
-2.62%
1M Performance:
+1.27%
6M Performance:
+65.64%
1Y Performance:
-59.63%
1-Day Range:
$16.06
$16.85
1-Week Range:
$16.01
$17.63
52-Week Range:
$5.95
$62.75
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Name
Moonlake Immunotherapeutics
Sector
Industry
Phone
41 41 510 8022
Address
DORFSTRASSE 29, ZUG
Compare MLTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
16.73 | 1.22B | 0 | -230.32M | -196.04M | -3.5259 |
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.50 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-23-26 | Upgrade | Wolfe Research | Underperform → Outperform |
| Mar-19-26 | Upgrade | Rothschild & Co Redburn | Neutral → Buy |
| Jan-15-26 | Downgrade | Goldman | Neutral → Sell |
| Jan-09-26 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-03-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-02-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-01-25 | Downgrade | Goldman | Buy → Neutral |
| Sep-30-25 | Downgrade | Citigroup | Buy → Neutral |
| Sep-30-25 | Downgrade | Wolfe Research | Outperform → Underperform |
| Sep-29-25 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-29-25 | Downgrade | Jefferies | Buy → Hold |
| Sep-29-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-29-25 | Downgrade | Stifel | Buy → Hold |
| Jul-28-25 | Initiated | Rothschild & Co Redburn | Neutral |
| May-19-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-18-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-17-25 | Upgrade | Goldman | Neutral → Buy |
| Nov-05-24 | Resumed | Wedbush | Outperform |
| Aug-26-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Nov-02-23 | Initiated | Stifel | Buy |
| Sep-14-23 | Downgrade | Bryan Garnier | Buy → Neutral |
| Aug-31-23 | Initiated | Needham | Buy |
| Jun-15-23 | Initiated | Barclays | Equal Weight |
| May-01-23 | Initiated | Guggenheim | Buy |
| Mar-22-23 | Initiated | Wedbush | Outperform |
| Mar-09-23 | Initiated | BTIG Research | Buy |
| Feb-14-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-02-23 | Initiated | Bryan Garnier | Buy |
| Nov-11-22 | Initiated | Jefferies | Buy |
| Aug-25-22 | Initiated | SVB Leerink | Outperform |
| Jul-21-22 | Initiated | H.C. Wainwright | Buy |
| Jul-07-22 | Initiated | Cowen | Outperform |
View All
Moonlake Immunotherapeutics Stock (MLTX) Latest News
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Short Interest in MoonLake Immunotherapeutics (NASDAQ:MLTX) Decreases By 14.2% - MarketBeat
MLTX Price Today: MoonLake Immunotherapeutics Stock Price, Quote & Chart | MEXC - MEXC Exchange
MoonLake plunges after mixed results from skin disease trial - MSN
MoonLake Immunotherapeutics (MLTX) Proxy Filing Summary - Quartr
MoonLake’s lead asset shows durability in late-stage HS studies - MSN
MLTX stock garners retail attention on buyout speculation, positive skin condition trial data - MSN
MLTX Stock Chart | MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ:MLTX) - ChartMill
Moonlake surges as no additional studies are required for lead drug - MSN
MoonLake Immunotherapeutics (MLTX) price target increased by 11.25% to 22.30 - MSN
Merck made $3B+ offer for MoonLake earlier this yearreport - MSN
Why Is MoonLake Immunotherapeutics Stock Crashing Premarket? - MSN
Understanding the Setup: (MLTX) and Scalable Risk - Stock Traders Daily
MoonLake Immunotherapeutics (NASDAQ: MLTX) puts 6.2% equity plan dilution to shareholder vote - Stock Titan
MoonLake Immunotherapeutics (MLTX) Proxy filing Summary - Quartr
The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock? - AOL.com
The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock? - The Motley Fool
Have Insiders Sold MoonLake Immunotherapeutics Shares Recently? - Sahm
Insider Sell: Matthias Bodenstedt Sells Shares of MoonLake Immun - GuruFocus
Biotech Fund BVF Trims MoonLake Stake, Sells $63M in Shares - AOL.com
MoonLake (MLTX) CFO sells 2,426 shares under Rule 10b5-1 plan - Stock Titan
H.C. Wainwright reiterates Moonlake stock rating on HS potential By Investing.com - Investing.com Australia
H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
H.C. Wainwright reiterates Moonlake stock rating on HS potential - Investing.com
Major Insider Move at MoonLake Immunotherapeutics Stirs Investor Attention - TipRanks
Insider Sell: CEO Santos da Silva Jorge Sells 150,000 Shares of MoonLake Immunotherapeutics (MLTX) - GuruFocus
MoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Da Silva Jorge Santos Sells 51,873 Shares - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Da Silva Jorge Santos Sells 98,127 Shares - MarketBeat
MoonLake Immunotherapeutics Chief Executive Officer Sold Shares Worth Over $2.7M - TradingView — Track All Markets
MoonLake Immunotherapeutics (NASDAQ: MLTX) CEO sells 150,000 company shares - Stock Titan
Needham Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Positive Risk-Reward and Strategic Momentum Underpin Buy Rating on MoonLake Immunotherapeutics - TipRanks
MoonLake ImmunotherapeuticsClass A Ordinary Shares (NQ: MLTX - The Chronicle-Journal
The Technical Signals Behind (MLTX) That Institutions Follow - Stock Traders Daily
Pre-planned MoonLake (NASDAQ: MLTX) CFO share sale totals 87,795 - Stock Titan
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 6%Here's Why - MarketBeat
Moonlake Immunotherapeutics Stock (MLTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Moonlake Immunotherapeutics Stock (MLTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Santos da Silva Jorge | Chief Executive Officer |
Apr 10 '26 |
Sale |
18.41 |
98,127 |
1,806,518 |
2,976,766 |
| Santos da Silva Jorge | Chief Executive Officer |
Apr 13 '26 |
Sale |
18.23 |
51,873 |
945,645 |
2,924,893 |
| Bodenstedt Matthias | Chief Financial Officer |
Apr 09 '26 |
Sale |
18.94 |
85,870 |
1,626,378 |
1,190,435 |
| Bodenstedt Matthias | Chief Financial Officer |
Apr 10 '26 |
Sale |
19.51 |
1,925 |
37,557 |
1,188,510 |
2.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):